Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma

British Journal of Cancer

Volumn 104, Issue 12, 2011, Pages 1840-1847

  Fields, R C ^a   Strong, V E ^a   Gonen M ^a   Goodman, K A ^a   Rizk, N P ^a   Kelsen, D P ^a   Ilson, D H ^a   Tang, L H ^a   Brennan, M F ^a   Coit, D G ^a   Shah, M A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

chemotherapy; gastric cancer; pathologic complete response; radiation therapy; surgery

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 79958134272     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.175     Document Type: Article

References (49)

1. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC (2010) Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 124(3): 723-732
2. Ajani JA (2005) Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol 23(19): 4256-4258 (Pubitemid 46206998)
3. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH (2007) Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 96(12): 1823-1827 (Pubitemid 46912031)
4. Anderson WF, Camargo MC, Fraumeni Jr JF, Correa P, Rosenberg PS, Rabkin CS (2010) Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303(17): 1723-1728
5. Bains MS, Stojadinovic A, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH (2002) A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 124(2): 270-277 (Pubitemid 35025602)
6. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23(19): 4330-4337 (Pubitemid 46207006)
7. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP (2004) Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22(1): 45-52 (Pubitemid 41095113)
8. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP (2006) A phase II trial of neoadjuvant cisplatin- fluorouracil followed by postoperative intraperitoneal floxur-idine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 17(9): 1404-1411 (Pubitemid 44403435)
9. Chabner B, Longo DL (2011) Cancer Chemotherapy and Biotherapy: Principles and Practice, 5th edn Wolters Kluwer/Lippincott Williams & Wilkins Health: Philadelphia
10. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA (2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99(6): 433-441 (Pubitemid 47073566)
11. Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP (2009) Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiother-apy. Ann Surg 249(3): 392-396
12. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM (2010) Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17): 4168-4177
13. Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA (2007) Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 109(8): 1668-1675 (Pubitemid 46595704)
14. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1): 11-20
15. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2): 392-398; discussion 398-399
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual, 7th edn Springer Science and Business Media LLC (SBM: New York)
17. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214. J Clin Oncol 29(3): 272-278
18. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3): 1141-1154
19. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr U, Silva e Sousa Jr AH, Campos FG, Kiss DR, Gama-Rodrigues J (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240(4): 711-717; discussion 717-718
20. Hundahl SA, Phillips JL, Menck HR (2000) The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 88(4): 921-932 (Pubitemid 30091113)
21. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300
22. Johnson PM, Porter GA, Ricciardi R, Baxter NN (2006) Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24(22): 3570-3575 (Pubitemid 46630528)
23. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150 (Pubitemid 46655601)
24. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
25. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10(4): 541-548
26. Kelsen D, Ginsberg R, Bains M, Cooper J, Arquette M, Forastiere AA, Ilson D (1997) A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol 24(6 Suppl 19): S19-77-S19-81
27. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9): 797-805 (Pubitemid 47308659)
28. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small Jr W, Suarez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9): 835-844
29. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10): 725-730
30. Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23(7): 1530-1537
31. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG (2007) Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 14(12): 3412-3418 (Pubitemid 350160134)
32. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS (2010) Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 105(2): 420-433
33. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14(7): 2012-2018 (Pubitemid 351551110)
34. Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD (2010) Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys; e-pub ahead of print 30 September 2010
35. Prentice RL, Kalbfleisch JD, Peterson Jr AV, Flournoy N, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biometrics 34(4): 541-554 (Pubitemid 9067879)
36. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M (2004) Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 47(11): 1798-1807 (Pubitemid 40064422)
37. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH (2008) Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 71(3): 741-747
38. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA (2005) Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7): 1349-1355 (Pubitemid 41356149)
39. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(7): 1229-1235 (Pubitemid 39424779)
40. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Cutsem EV, Siewert JR, Schlag PM (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28(35): 5210-5218
41. Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, Gross H, Willett C, Kelsen D (2009) Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol 27(12): 1956-1962
42. Shah MA (2007) A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome. ASCO Annu Meet
43. Shah MA (2011) Pre-operative chemotherapy plus bevacizumab with early salvage therapy based on PET assessment of response in patients with locally advanced but resectable gastric and GEJ adenocarci-noma (clinicaltrials.gov NCT00737438). http://clinicaltrials.gov/ct2/show/NCT00737438?term=pre- operative+chemotherapy+plus+bevacizumab&rank=1
44. Shah MA, Ajani JA (2010) Gastric cancer-an enigmatic and heterogeneous disease. JAMA 303(17): 1753-1754
45. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6): 851-856
46. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28): 4414-4422 (Pubitemid 350013847)
47. Wieder H, Weber W (2009) Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction. Eur J Nucl Med Mol Imaging 36(1): 158-159
48. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102
49. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS (2009) Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 18(7): 1945-1952